EUVIMEDEUVIMED entdecken
Crossref

Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate

Ruonan Zhao, Peng Wan, Honghao Huang, Qi Li, Zhenling Zeng, Wenguang Xiong iD

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf442 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Ruonan Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricu…. Hauptthemen laut MEDLINE: Escherichia coli, CRISPR-Cas Systems, Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Key R&D Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the CRISPR–Cas9 and CRISPR interference (CRISPRi) systems as an antibiotic re-sensitization strategy for reversing multidrug resistance in a clinical Escherichia coli isolate. Materials and methods The CRISPR–Cas9 system was applied for precise deletion of the acrB gene from clinical E. coli isolate GP53 and homologous recombination (HR) was provided for accurate repairs of double-strand breaks. An arabinose-inducible CRISPRi system was developed and optimized using fluorescent reporter strain GH01. Multiple guide RNAs (gRNAs) targeting acrB were designed, and the most effective gRNA was selected based on its transcriptional suppression of gene acrB. The minimum inhibitory concentrations (MICs) of selected antibiotics in GP53ΔacrB, CRISPRi strains, WT and WT combined with efflux pump inhibitor PAβN were evaluated.

Results

The CRISPR–Cas9 system precisely deleted the acrB gene in clinical E. coli isolate GP53 with 11.46% knockout efficiency. The constructed arabinose-inducible CRISPRi system effectively repressed fluorescent protein expression in strain GH01. Although dCas9 expression increased with L-arabinose concentration, the transcriptional repression efficiency of the target gene under 1 mM induction reached a significant inhibitory level. The CRISPRi system targeting gene acrB exhibited 44.9%, 5.4% and 23.5% inhibition rates on the transcriptional levels with 1 mM L-arabinose for three distinct gRNAs. Both the knockout and CRISPRi strains successfully restored susceptibility of the multidrug-resistant E. coli GP53 to quinolones and tetracyclines, outperforming the effect of PAβN combination therapy.

Conclusions

In this study, CRISPR-based systems effectively reversed multidrug resistance in a clinical E. coli isolate, advancing the applications of CRISPR systems in controlling bacterial multidrug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coliCRISPR-Cas SystemsDrug Resistance, Multiple, BacterialAnti-Bacterial AgentsMicrobial Sensitivity TestsEscherichia coli ProteinsEscherichia coli InfectionsHumansATP-Binding Cassette, Sub-Family C ProteinsRNA, Guide, CRISPR-Cas SystemsGene Deletion

Substanzen

Anti-Bacterial AgentsEscherichia coli ProteinsATP-Binding Cassette, Sub-Family C ProteinsRNA, Guide, CRISPR-Cas SystemsAcrB protein, E coli

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
  • National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.

ORCID-Profile: Wenguang Xiong

Förderung

  • National Key R&D Program

Zitieren

APA

Zhao, R., Wan, P., Huang, H., Li, Q., Zeng, Z., & Xiong, W. (2026). Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf442

Vancouver

Zhao R, Wan P, Huang H, Li Q, Zeng Z, Xiong W. Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf442

BibTeX
@article{Zhao2026,
  author = {Zhao, Ruonan and Wan, Peng and Huang, Honghao and Li, Qi and Zeng, Zhenling and Xiong, Wenguang},
  title = {Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf442}
}
Kostenlos starten →